The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Long-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for Acromegaly1
Abstract
To analyze the long term outcome after multimodality therapy for acromegaly, a retrospective review was performed on 162 patients who underwent transsphenoidal surgery at Massachusetts General Hospital between 1978 and 1996. The surgical cure rate for microadenomas was 91%, that for macroadenomas was 48%, and it was 57% overall. The surgical cure rate was significantly dependent on tumor size, but was not dependent on age or sex. An improvement in the surgical cure rate was noted over the course of the review, from 45% before 1987 to 73% since 1991. Long term follow-up was obtained in 99% of U.S. residents (149 of 151), with a mean follow-up period of 7.8 yr. Adjuvant radiation and/or pharmacological therapy was given to 61 patients. Of the entire group, 83% (124 of 149) were in biochemical remission as determined by normalization of serum insulin-like growth factor I levels or by GH suppression after oral glucose tolerance testing at last contact or at death. The recurrence rate was 6% at 10 yr and 10% at 15 yr after surgery in those patients who initially met the criteria for surgical cure. The 10-yr survival rate was 88%, and there were 12 deaths at postoperative intervals of 2-12 yr, with the most common cause of death being cardiovascular disease. A Cox proportional hazards model showed that patient-years with persistent disease carried a 3.5-fold [95% confidence interval (CI), 1.0-12; P = 0.02] relative mortality risk compared to those patient-years in remission. A Poisson person-years regression analysis showed no significant difference in survival between those 86 patients cured at operation and an age- and sex-matched sample from the U.S. population [standardized mortality ratio (SMR), 0.84; 95% CI, 0.3-2.2; P = 0.35]. A similar analysis on the entire group of 149 patients showed no significant difference in survival from that in a control sample (SMR, 1.16; 95% CI, 0.66-2.0; P = 0.3). Mortality risk for patient-years with persistent active disease after unsuccessful treatment vs. that in the U.S. population sample remained increased (SMR, 1.8; 95% CI, 0.9-3.6; P = .05). This analysis suggests that the decreased survival previously reported to be associated with acromegaly can be normalized by successful surgical and adjunctive therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Kupper, L. L., Hosmer, D. W., & Lemeshow, S. (1990) · Journal of the American Statistical Association · doi:10.2307/2290035 · Cited by 7,599
Survival Analysis, Techniques for Censored and Truncated Data
Rao, M. B. (1998) · Technometrics · doi:10.1080/00401706.1998.10485206 · Cited by 3,617
Determinants of clinical outcome and survival in acromegaly
Rajasoorya, C., Holdaway, I. M., Wrightson, P., Scott, D. J., & Ibbertson, H. K. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb03789.x · Cited by 565
Wright, A. D., Hill, D. M., Lowy, C., & Fraser, T. R. (1970) · PubMed · Cited by 529
BENGTSSON, B., EDÉN, S., ERNEST, I., ODÉN, A., & SJÖGREN, B. (1988) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1988.tb15881.x · Cited by 528
EPIDEMIOLOGY OF ACROMEGALY IN THE NEWCASTLE REGION
ALEXANDER, L., APPLETON, D., HALL, R., ROSS, W. M., & WILKINSON, R. (1980) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1980.tb03135.x · Cited by 466
An audit of outcome of treatment in acromegaly
(1993) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068816 · Cited by 466
Survival Analysis Techniques for Censored and Truncated Data
Klein, J. P., & Moeschberger, M. L. (2003) · Thammasat University Digital Collections · Cited by 360
The Analysis of Mortality by the Subject-Years Method
Berry, G. (1983) · Biometrics · doi:10.2307/2530817 · Cited by 278
Cited by
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management
Colao, A., Ferone, D., Marzullo, P., & Lombardi, G. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0022 · Cited by 1,309
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Melmed, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062453 · Cited by 1,160
Criteria for Cure of Acromegaly: A Consensus Statement
Giustina, A. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.526 · Cited by 987
Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant
Trainer, P. J., Drake, W. M., Katznelson, L., Freda, P. U., Herman-Bonert, V., van der Lely, A. J., Dimaraki, E. V., Stewart, P. M., Friend, K. E., Vance, M. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004203421604 · Cited by 879
Self-citationGuidelines for Acromegaly Management: An Update
Melmed, S., Colao, A., Barkan, A., Molitch, M., Grossman, A. B., Kleinberg, D., Clemmons, D., Chanson, P., Laws, E., Schlechte, J., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2421 · Cited by 764
Factors Influencing Mortality in Acromegaly
Holdaway, I. M., Rajasoorya, R. C., & Gamble, G. D. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031199 · Cited by 651
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
van der Lely, A. J., Hutson, R. K., Trainer, P. J., Besser, G. M., Barkan, A. L., Katznelson, L., Klibanski, A., Herman-Bonert, V., Melmed, S., Vance, M. L., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06844-1 · Cited by 645
Self-citationMortality in Acromegaly: A Metaanalysis
Dekkers, O. M., Biermasz, N. R., Pereira, A. M., Romijn, J. A., & Vandenbroucke, J. P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1191 · Cited by 517
Barker, F. G., Klibanski, A., & Swearingen, B. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030461 · Cited by 506
Self-citationThe outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’
Nomikos, P., Buchfelder, M., & Fahlbusch, R. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01863 · Cited by 500
A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly
Holdaway, I. M., Bolland, M. J., & Gamble, G. D. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0267 · Cited by 462
Mortality in Patients with Pituitary Disease
Sherlock, M., Ayuk, J., Tomlinson, J. W., Toogood, A. A., Aragon-Alonso, A., Sheppard, M. C., Bates, A. S., & Stewart, P. M. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0033 · Cited by 392
Colao, A., Marzullo, P., Di Somma, C., & Lombardi, G. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01218.x · Cited by 388
Mestron, A., Webb, S., Astorga, R., Benito, P., Catala, M., Gaztambide, S., Gomez, J., Halperin, I., Lucas-Morante, T., Moreno, B., et al. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510439 · Cited by 387
Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly
Kopchick, J. J., Parkinson, C., Stevens, E. C., & Trainer, P. J. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0022 · Cited by 352
Roelfsema, F., Biermasz, N. R., & Pereira, A. M. (2012) · Pituitary · doi:10.1007/s11102-011-0347-7 · Cited by 346
Ayuk, J., Clayton, R. N., Holder, G., Sheppard, M. C., Stewart, P. M., & Bates, A. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031584 · Cited by 343
Guidelines for Acromegaly Management
Melmed, S., Casanueva, F. F., Cavagnini, F., Chanson, P., Frohman, L., Grossman, A., Ho, K., Kleinberg, D., Lamberts, S., Laws, E., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-011841 · Cited by 343
Kreutzer, J., Vance, M. L., Lopes, M. B. S., & Laws, E. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.9.4072 · Cited by 341
Long‐term outcome and mortality after transsphenoidal adenomectomy for acromegaly
Beauregard, C., Truong, U., Hardy, J., & Serri, O. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01679.x · Cited by 300
Somatostatin Analogs in Acromegaly
Freda, P. U. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.7.3013 · Cited by 298
Bevan, J. S., Atkin, S. L., Atkinson, A. B., Bouloux, P.-M., Hanna, F., Harris, P. E., James, R. A., McConnell, M., Roberts, G. A., Scanlon, M. F., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2001-012012 · Cited by 279
A Nationwide Survey of Mortality in Acromegaly
Kauppinen-Mäkelin, R., Sane, T., Reunanen, A., Välimäki, M. J., Niskanen, L., Markkanen, H., Löyttyniemi, E., Ebeling, T., Jaatinen, P., Laine, H., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1381 · Cited by 269
Somatostatin Analogs in Clinical Practice: A Review
Gomes-Porras, M., Cárdenas-Salas, J., & Álvarez-Escolá, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051682 · Cited by 264
Consensus guidelines on screening for hypopituitarism following traumatic brain injury
Ghigo, E., Masel, B., Aimaretti, G., Léon-Carrión, J., Casanueva, F. F., Dominguez-Morales, M. R., Elovic, E., Perrone, K., Stalla, G., Thompson, C., et al. (2005) · Brain Injury · doi:10.1080/02699050400025315 · Cited by 261
(2011) · Endocrine Practice · doi:10.4158/ep.17.s4.1 · Cited by 259
Resistance to Somatostatin Analogs in Acromegaly
Colao, A., Auriemma, R. S., Lombardi, G., & Pivonello, R. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0002 · Cited by 257
Biermasz, N. R., van Thiel, S. W., Pereira, A. M., Hoftijzer, H. C., van Hemert, A. M., Smit, J. W. A., Romijn, J. A., & Roelfsema, F. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0669 · Cited by 254
Sherlock, M., Reulen, R. C., Alonso, A. A., Ayuk, J., Clayton, R. N., Sheppard, M. C., Hawkins, M. M., Bates, A. S., & Stewart, P. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1097 · Cited by 185
Outcomes of proton therapy for patients with functional pituitary adenomas
Wattson, D. A., Tanguturi, S. K., Spiegel, D. Y., Niemierko, A., Biller, B. M. K., Nachtigall, L. B., Bussière, M. R., Swearingen, B., Chapman, P. H., Loeffler, J. S., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.06.068 · Cited by 125
Self-citationHypogonadism in patients with acromegaly: data from the multi‐centre acromegaly registry pilot study
Katznelson, L., Kleinberg, D., Vance, M. L., Stravou, S., Pulaski, K. J., Schoenfeld, D. A., Hayden, D. L., Wright, M. E., Woodburn, C. J., & Klibanski, A. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01214.x · Cited by 95
Self-citationYedinak, C., Hameed, N., Gassner, M., Brzana, J., McCartney, S., & Fleseriu, M. (2015) · Pituitary · doi:10.1007/s11102-015-0643-8 · Cited by 27
Metadata
- Authors
- Swearingen, B., Barker, F. G., Katznelson, L., Biller, B. M. K., Grinspoon, S., Klibanski, A., Moayeri, N., Black, P. M., & Zervas, N. T.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1998-10
- Volume
- 83
- Issue
- 10
- Pages
- 3419-3426
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2017091398
- Cited by
- 586
- References
- 22
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.